Datwyler, a provider of high-value, system-critical elastomer components, announced a collaboration with LTS Device Technologies, a developer of smart wearable devices for drug delivery, and Stevanato Group, a leading global provider of drug containment, drug delivery, and diagnostic solutions.
Together the companies aim to broaden the scope of large-volume subcutaneous drug delivery by enabling convenient on-body administration of larger volumes – meeting the evolving needs of patients, alongside market demands.
The three companies will unveil their platform solution at a joint Learning Lab presentation: When Size Matters: The Evolution of Self-Delivery Solutions for Subcutaneous Administration at Pharmapack, Jan 21-22,2026 in Paris, France.
Patient-centric healthcare
The pharmaceutical landscape for subcutaneous drug delivery is undergoing rapid transformation, driven by the increasing use of biologics and other sensitive therapeutics in clinical practice. According to Precedence Research, the US biologics market is projected to reach US$483 billion by 2034, as small molecule research and development productivity declines.
At the same time, patient preferences are changing. A recent Mayo Clinic study (Mayo Clinic’s) found that 73% of participants favored in-home self-administration after 24 weeks of therapy – underscoring the need for solutions that support decentralized, convenient patient-centric healthcare versus hospitals or other medical settings.
“By enabling patients to self-administer therapies at home, subcutaneous drug administration facilitates a growing shift towards more accessible personalized healthcare. Datwyler’s spray coated NeoFlex plungers increase the functional reliability of large volume injection systems and promote greater comfort and safety for the patients,” said Paolo Ferrigno, product manager, PFS & Cartridges, Datwyler.
Overcoming the challenges of on-body delivery for large-volume therapies
Transitioning from hospital-based administration to at-home delivery for large volume, highly sensitive biologics, and other formulations present unique challenges, such as pain, tissue tolerability, and absorption kinetics for high-volume therapies have limited subcutaneous injections to lower volumes, typically 2mL or less.
High-dose therapies, such as monoclonal antibodies, oncology treatments, and long-acting neurologic formulations, often exceed the limits of conventional low-volume delivery. The design of a new custom delivery solution may not always be feasible for pharmaceutical and medical device manufacturers in a competitive market.
Riccardo Marcon, senior vice president sales and marketing of drug containment solutions with Stevanato Group commented, “There is a pressing market need for innovative solutions to support larger volumes of up to 20mL in a self-administered setting while strictly maintaining safety, therapeutic efficacy, and patient compliance. For pharma companies, EZ-fill Large Volume Cartridges have been the ideal solution to reduce their complex operations for more than a decade. Our market-leading ready-to-use, EZ-fill® containers are supplied pre-washed, pre-siliconized, pre-assembled with front stoppers, packed in Nest & Tub and pre-sterilized.”
Collaborating for solutions
Anticipating these market challenges, the collaboration has joined forces to offer a pre-verified ecosystem for faster market access, featuring:
Datwyler’s extended range of NeoFlex plungers for larger volume containers to enable slow, controlled drug delivery and support a wider range of self-administration devices.
Stevanato Group’s market-leading large-volume, ready-to-use EZ-fill cartridges to address the unique challenges in sensitive therapies, and,
LTS Device Technologies’ Sorrel Platform, capable of delivering from 10 and 20mL cartridges, hence an appropriate choice to demonstrate the capabilities of the NeoFlex™ plungers and large-volume, ready-to-use EZ-fill cartridges.
The companies will showcase the collaboration to evolve container closure system (CCS) development by optimizing pre-verified platform solutions at Pharmapack with a learning lab presentation, ‘When Size Matters: The Evolution of Self-Delivery Solutions for Subcutaneous Administration,’ which will be held on Thursday, 22 January at 12:50 p.m. CET in the Learning Labs – 4A89.
Presenters include Paolo Ferrigno, product manager, PFS & Cartridges, Datwyler; Valerio Ravazzolo, product manager, cartridge platform, Stevanato Group; and Greg Moakes, EVP, new business development, LTS Device Technologies.
